Supercharge Your Innovation With Domain-Expert AI Agents!

Application of Ternatusine A in preparation of drugs for treating renal insufficiency

A technology for renal insufficiency, applied in the application field of Ternatusine A in the preparation of drugs for the treatment of renal insufficiency, which can solve the problems of high toxicity and side effects, high price, and dependence on imports, and achieve the effect of highlighting substantive characteristics and strong therapeutic activity

Inactive Publication Date: 2017-01-25
ZIBO DINGLI PATENT INFORMATION CONSULTING CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Benazepril and Losartan are currently clinically used to treat renal insufficiency, but they mainly rely on imports. These drugs are expensive and have relatively high toxicity and side effects.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Ternatusine A in preparation of drugs for treating renal insufficiency
  • Application of Ternatusine A in preparation of drugs for treating renal insufficiency
  • Application of Ternatusine A in preparation of drugs for treating renal insufficiency

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] Embodiment 1: the preparation of compound Ternatusine A tablet involved in the present invention:

[0016] Take 5 grams of compound Ternatusine A and add 195 grams of dextrin, mix well, and make 1000 tablets by conventional tableting.

Embodiment 2

[0017] Embodiment 2: the preparation of the compound Ternatusine A capsule involved in the present invention:

[0018] Get 5 grams of compound Ternatusine A, add 195 grams of starch, mix well, and make 1000 capsules.

[0019] The following pharmacodynamic experiments will further illustrate its drug activity.

experiment example 1

[0020] Experimental Example 1: Study on the Effect of Ternatusine A on the Acute Kidney Injury Model in Mice

[0021] 1. Establishment of cisplatin-induced acute kidney injury model in mice: Male Kunming KM mice, 16-18 g, were randomly divided into solvent control group, cisplatin model group, and administration group according to body weight, a total of 6 groups, each group 8 only. The control group was intraperitoneally injected with normal saline, and cisplatin was dissolved in normal saline and injected intraperitoneally at 7 mg / kg. The compound of the present invention began to be administered orally 2 days before the injection of cisplatin, once a day, and was administered five times in total; the positive control drug Benazepril (K) was orally administered at the same time when injecting cisplatin, once a day, for a total of five times. Three times of administration (the effect of administration 2 days before the injection of cisplatin is not as good as that of simulta...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of Ternatusine A in the preparation of drugs for treating renal insufficiency and belongs to the technical field of novel applications of drugs; the application is disclosed for the first time; since a framework is of brand-new type, the inhibitory activity of Ternatusine A for renal insufficiency is high and outstanding practical characteristics are provided; in addition, Ternatusine A has significant progress in controlling renal insufficiency.

Description

technical field [0001] The present invention relates to the new application of compound Ternatusine A, in particular to the application of Ternatusine A in the preparation of drugs for treating renal insufficiency. Background technique [0002] Chronic kidney disease (including various chronic nephritis, diabetic nephropathy and hypertensive renal damage, etc.) is the most common chronic refractory disease. Renal tissue lesions will gradually progress from early lesions to advanced lesions of glomerulosclerosis and / or interrenal fibrosis. If it is not treated effectively, it will eventually lead to chronic renal insufficiency and irreversible end-stage renal failure (ie uremia). Benazepril and Losartan are currently clinically used to treat renal insufficiency, but they mainly rely on imports. These drugs are expensive and have relatively high toxicity and side effects. Such as causing some patients hyperkalemia, insurmountable cough, blood pressure lowering effect is not ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/407A61P13/12
CPCA61K31/407
Inventor 田丽华
Owner ZIBO DINGLI PATENT INFORMATION CONSULTING CO LTD
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com